Mi­cro­bio­me pi­o­neer Seres crushed as lead drug flops in PhII

One of the pi­o­neers in the mi­cro­bio­me R&D world has slammed in­to a Phase II fail­ure for its lead pro­gram. Seres Ther­a­peu­tics $MCRB says that SER-109 flunked a mid-stage test for re­duc­ing the re­cur­rence of Clostrid­i­um dif­fi­cile in­fec­tion.

SER-109 bare­ly im­proved on the per­for­mance of a place­bo in the study, with 44% in the mi­cro­bio­me drug arm see­ing a re­cur­rence of CDI, com­pared to 53% in the sug­ar pill group. That’s not near­ly good enough to qual­i­fy as a sig­nif­i­cant im­prove­ment.

Seres’s stock was crushed, plum­met­ing 78% in pre­mar­ket trad­ing and wip­ing out the li­on’s share of its $1.4 bil­lion mar­ket cap.

Seres is part of a group of star­tups that are work­ing with a bugs-to-drugs strat­e­gy, us­ing spores from a se­lect group of bac­te­ria to re­store the prop­er mi­cro­bial bal­ance need­ed to main­tain health and fight af­flic­tions like CDI. The com­pa­ny raised more than $130 mil­lion be­fore go­ing pub­lic.

The set­back is al­so bad news for Nestlé Health Sci­ence, which paid $120 mil­lion up­front to part­ner on CDI at the be­gin­ning of the year. The pact in­clud­ed some $2 bil­lion in mile­stones for four pro­grams, along with a com­mit­ment to help pay for late-stage de­vel­op­ment.

The Cam­bridge, MA-based com­pa­ny is one of sev­er­al mi­cro­bio­me play­ers to set up shop in Cam­bridge, MA. Not far from their base you can al­so find Vedan­ta and Syn­log­ic, while out in San Fran­cis­co, Sec­ond Genome is promis­ing to make its own mi­cro­bial waves. Any doubts raised at one of these com­pa­nies may well cast a pall over the emerg­ing field.

Seres, though, is vow­ing to over­come the first big clin­i­cal blowup for ex­per­i­men­tal mi­cro­bio­me drugs.

Seres CEO Roger Pomer­antz

“These are un­ex­pect­ed clin­i­cal re­sults in view of the pos­i­tive da­ta in our pri­or in­ves­ti­ga­tor-spon­sored Phase Ib tri­al, as well as in a wide range of sup­port­ing clin­i­cal and pre­clin­i­cal da­ta,” not­ed Seres CEO Roger Pomer­antz. “Specif­i­cal­ly, the re­cur­rence rates ob­served in the over­all SER-109 treat­ment group, in the age strat­i­fied sub­groups, and in the place­bo groups are in­con­sis­tent with our ex­pec­ta­tions. Our pri­or­i­ty is to com­plete a full re­view of the clin­i­cal re­sults and mi­cro­bio­me da­ta of the Phase 2 study and to com­pare it to da­ta from the pri­or in­ves­ti­ga­tor spon­sored Phase 1b. Based on this in­for­ma­tion and pend­ing dis­cus­sions with the FDA, we plan to make any nec­es­sary changes to our de­vel­op­ment plans for SER-109.”

Hal Barron and Rick Klausner (GSK, Lyell)

Ex­clu­sive: GSK’s Hal Bar­ron al­lies with Rick Klaus­ner’s $600M cell ther­a­py start­up, look­ing to break new ground blitz­ing sol­id tu­mors

LONDON — Chances are, you’ve heard little or nothing about Rick Klausner’s startup Lyell. But that ends now.

Klausner, the former head of the National Cancer Institute, former executive director for global health at the Gates Foundation, co-founder at Juno and one of the leaders in the booming cell therapy field, has brought together one of the most prominent teams of scientists tackling cell therapy 2.0 — highlighted by a quest to bridge a daunting tech gap that separates some profound advances in blood cancers with solid tumors. And today he’s officially adding Hal Barron and GlaxoSmithKline as a major league collaborator which is pitching in a large portion of the $600 million he’s raised in the past year to make that vision a reality.

“We’ve being staying stealth,” Klausner tells me, then adding with a chuckle: “and going back to stealth after this.”

“Cell therapy has a lot of challenges,” notes Barron, the R&D chief at GSK, ticking off the resistance put up by solid tumors to cell therapies, the vein-to-vein time involved in taking immune cells out of patients, engineering them to attack cancer cells, and getting them back in, and more. “Over the years Rick and I talked about how it would be wonderful to take that on as a mission.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

First place fin­ish: Eli Lil­ly just moved to fran­chise leader with their sec­ond mi­graine drug OK in 1 year

In a rare twist for Eli Lilly’s historically slow-moving R&D group, the pharma giant has seized bragging rights to a first-in-class new drug approval. And all signs point to an aggressive marketing followup as they look to outclass some major franchise rivals hobbled by internal dissension.

The FDA came through with an OK for lasmiditan on Friday evening, branding it as Reyvow and lining it up — once a substance classification comes through from the DEA — for a major market release. The oral drug binds to 5-HT1F receptors and is designed to stop an acute migraine after it starts. That makes it a complementary therapy to their CGRP drug Emgality, which has a statistically significant impact on preventing attacks.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

Allogene HQ Open House on September 17, 2019 in South San Francisco. (Jeff Rumans, Endpoints News)

The next 10 years: Where is biotech head­ed?

The last 10 years have seen a revolution in drug development. Timelines have shortened, particularly in oncology. Regulators have opened up. Investment has skyrocketed. China became a player. Biotechs have multiplied as gene and cell therapy has exploded — offering major new advances in the way diseases are treated, and sometimes cured.

So where are we headed from here? I journeyed out to San Francisco in September to discuss the answer to that question at Allogene’s open house. If the last 10 years have been an eye-opener, what does the next decade hold in store?

Patrick Mahaffy, Getty Images

Court green-lights Clo­vis case af­ter de­tail­ing ev­i­dence the board ‘ig­nored red flags’ on false safe­ty and ef­fi­ca­cy da­ta

Clovis investors have cleared a major hurdle in their long-running case against the board of directors, with a Delaware court making a rare finding that they had a strong enough case against the board to proceed with the action.

In a detailed ruling at the beginning of the month that’s been getting careful scrutiny at firms specializing in biotech and corporate governance, the Delaware Court of Chancery found that the attorneys for the investors had made a careful case that the board — a collection of experts that includes high-profile biotech entrepreneurs, a Harvard professor and well-known investigator as well as Clovis CEO Patrick Mahaffy — repeatedly ignored obvious warnings that Mahaffy’s executive crew was touting inflated, unconfirmed data for their big drug Roci. Serious safety issues were also reportedly overlooked while the company continued a fundraising campaign that brought in more than a half-billion dollars. And that leaves the board open to claims related to their role in the fiasco.

The bottom line:

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bill Gates backs Gink­go Biowork­s' $350M raise to fu­el the buzzy syn­thet­ic bi­ol­o­gy 'rev­o­lu­tion'

If you want to understand Ginkgo Bioworks, the name should suffice: Bioworks, a spin off “ironworks,” that old industrial linchpin devoted to leveraging scale as a wellspring for vast new industries capable of remaking society. Ginkgo wants to be the ironworks for the revolution it’s heralded with as much fanfare as they can, playing off of one of the buzziest technologies in biotech.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

UCB bags a ri­val to Soliris in $2.1B buy­out deal — but will an in­creas­ing­ly vig­i­lant FTC sign off?

UCB is buying out Ra Pharma $RARX, announcing an acquisition deal that rings up at $48 a share, or $2.1 billion net of cash, and puts them toe-to-toe with Alexion on a clinical showdown.

Ra shares closed at $22.70 on Wednesday.

There’s a small pipeline in play at Ra, but UCB is going for the lead drug — a C5 inhibitor called zilucoplan in Phase III for myasthenia gravis (MG) looking to play rival to Alexion’s Soliris. Soliris has the market advantage, though, with a much earlier approval in MG in late 2017 that UCB feels confident in challenging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

A new play­er is tak­ing the field in a push for a he­mo­phil­ia A gene ther­a­py, and it’s a big one

BioMarin, the execs at Spark (and buyer-to-be Roche) as well as the Sangamo/Pfizer team have a new rival striding onto the hemophilia block. And it’s a big one.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

Stuck with a PhI­II gene ther­a­py fail­ure at 96 weeks, Gen­Sight prefers the up­beat as­sess­ment

Two years after treatment, the best thing that GenSight Biologics $SIGHT can say about their gene therapy for vision-destroying cases of Leber Hereditary Optic Neuropathy is that it’s just a bit better than a placebo — just maybe because one treatment can cover both eyes.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

George Scangos / Credit: Cornell University

ARCH, Soft­Bank-backed Vir Biotech­nol­o­gy un­der­whelms with $143 mil­lion IPO

George Scangos went back to Wall Street, and came back 700 million pennies short.

Scangos’ vaunted startup Vir Biotechnology raised $143 million in an IPO they hoped would earn $150 million. Shares were priced at $20, the low-end of the $20-$22 target.

Launched with backing from ARCH Venture’s Robert Nelsen, Masayoshi Son’s SoftBank Vision Fund, and the Bill & Melinda Gates Foundation, the infectious disease startup was one of a new wave of well-resourced biotechs that emerged with deep enough coffers to pursue a full R&D line rather than slowly build their case by picking off a single lead program.